This post was part of the Break Up with Your Makeup program sponsored by Galderma Laboratories, L.P. through their partnership with POPSUGAR. While I was compensated by POPSUGAR to write a post about Galderma Laboratories, L.P, all opinions are my own. You should discuss any medications with your doctor.
Ever been in a rush and not had the time for makeup, but also not had the confidence to go without because of rosacea symptoms? Galderma Laboratories, L.P. is trying to help YOU Break Up with Your Makeup and let your natural beauty shine through!
Galderma’s Mirvaso® (brimonidine) topical gel, 0.33%* is the first and only FDA- approved treatment developed and indicated for the persistent facial redness of rosacea. Facial redness is a common symptom of rosacea, a chronic, inflammatory skin condition that affects an estimated 16 million Americans. Instead of helping to treat it, most of the ads and articles I see out there are telling you to just cover it up. No one should be a slave to their makeup! In fact, certain cosmetics can actually exacerbate rosacea symptoms.
Just apply Mirvaso Gel to your face, evenly as a thin layer, avoiding the eyes and lips, once daily and it may start working in as little as 30 minutes. Mirvaso Gel won’t just cover up redness, it may reduce redness for up to 12 hrs. Talk to your doctor to see if Mirvaso Gel is right for you.
In the meantime, get ready to Break Up with Your Makeup and join us by voting for your favorite no-makeup selfie for a chance to win one of three $500 gift cards. ENTER HERE
Important Safety Information – Mirvaso® Gel*
Indication: Mirvaso® (brimonidine) topical gel, 0.33%* is an alpha-2 adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin- burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
*Each gram of gel contains 5mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit WWW.FDA.GOV/MEDWATCH or call 1-800-FDA-1088.
All trademarks are the property of their respective owners.